Showing all 3 results
Lamivudine & Zidovudine tablets
FreeProduct Composition & Strength
We supply this product in the internationally standardized Fixed-Dose Combination (FDC) required for therapeutic compliance.
Active Ingredient Strength (per Tablet) Primary Clinical Function Lamivudine (3TC) IP/BP/USP 150 mg The Chain Terminator: High potency, low toxicity. Zidovudine (AZT) IP/BP/USP 300 mg The Foundation: Proven efficacy in preventing replication. Excipients Pharma Grade The Matrix: Ensures stability of the sensitive FDC. Lamivudine Tablets
FreeProduct Composition & Available Portfolio strengths
We manufacture Lamivudine across the precise compendial strengths mandated to manage either targeted chronic hepatic monotherapy or high-potency systemic combination antiretroviral protocols.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lamivudine USP / BP / IP 100 mg Oral Solid Film-Coated Tablet Chronic Hepatitis B (HBV): Low-dose configuration optimized for standalone daily suppression of active hepatic viral replication. Lamivudine USP / BP / IP 150 mg Oral Solid Film-Coated Tablet Standard Antiretroviral (HIV): Baseline strength designed for twice-daily co-administration or integration into standard multi-drug ARV regimens. Lamivudine USP / BP / IP 300 mg Oral High-Potency Solid Tablet High-Compliance Antiretroviral (HIV): Standard adult once-daily high-dose format engineered to optimize long-term patient compliance. Lamivudine, Zidovudine & Nevirapine Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (often White or Off-White). This FDC is designed for patients who have successfully completed the Nevirapine “lead-in” phase.
Active Ingredient Strength (Standard) Class Lamivudine USP/BP 150 mg NRTI (Cytidine Analog) Zidovudine USP/BP 300 mg NRTI (Thymidine Analog) Nevirapine USP/BP 200 mg NNRTI Excipients Q.S. Microcrystalline Cellulose / Sodium Starch Glycolate
